Compare M&T Bank Corporation (MTB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Zoetis Inc — how do they compare? M&T Bank Corporation trades at $248.99 (market cap $36.15B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: M&T Bank Corporation and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| MTB | ZTS | |
|---|---|---|
Market Cap | $36.15B | $31.95B |
Sector | Financials | Health |
52-Week High | $254.04 | $156.76 |
52-Week Low | $178.63 | $71.91 |
Dividend Yield | 2.41% | 2.78% |
Enterprise Value | — | $39.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $248.66, down 0.23% on the day, with a bullish technical outlook supported by moving averages and strong support near $248. The stock shows solid fundamentals, including a P/E of 13.2, net income margin of 30.85%, and three consecutive quarterly EPS beats, most recently with Q2 2026 actual EPS of $5.35 versus $4.66 expected. Revenue growth is steady, reaching $9.63 billion in 2025, and the company maintains a dividend, with H1-26 paying $1.50 per share.
The outlook for MTB is positive, driven by earnings momentum and analyst consensus, though risks include elevated debt levels and potential macroeconomic pressures on net interest income. With a consensus price target of $253.68 and 62.5% of analysts rating it Hold, the stock offers moderate upside with a focus on execution and loan growth sustainability.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
